Sortase-Mediated Peptide Ligation and Cyclization for Phage Display

06 February 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Macrocyclic peptide library has proven to be an invaluable source for discovering high-affinity ligands for disease-associated proteins. Here we propose a sortase-mediated peptide ligation and one-pot cyclization strategy to generate monocyclic and bicyclic peptide libraries. Employing the promiscuity of sortase on the X site of the LPXTG motif, we introduce a low-reactive electrophile to the X residue for side-chain cyclization with the cysteine residue of an N-terminal glycine peptide. We combine the SrtA-mediated peptide cyclization strategy with phage display to construct a large-scale genetically encoded cyclopeptide library. After three-round in vitro selection, we identify a potent bicyclic peptide that binds TEAD4 with a nanomolar KD value (63.9 nM) and effectively blocks the TEAD۰YAP interaction. Importantly, the binding affinity of the bicyclic peptide ligand is 102 times lower than that of the noncyclized analogue. This SrtA-based phage display platform will provide a versatile technique for the discovery of macrocyclic peptide ligands.

Keywords

phage display
macrocyclic peptide library
sortase-A-mediated ligation
macrocyclization
bicyclic peptide

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Detailed description of the experiments, analysis of the compounds mentioned in the study, and characterisation and activity testing of macrocyclic peptides.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.